Week of May 24th, 2021 | Vol. 10, Issue 21
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Ashfield Engage, part of UDG Healthcare plc., announces the closure of the acquisition of Nuvera LLC, a US-based healthcare consulting firm specializing in patient support programs.

Nuvera are experts in optimizing the design and build of seamless patient and HCP treatment experiences. This expertise will enhance Ashfield Engage’s Patient Solutions capabilities and create an end-to-end strategic offering across their client’s product lifecycles.

Following the acquisition, Ashfield Engage and Nuvera will offer integrated specialist support and services including late-phase clinical trial experience, implementation and post-commercialization satisfaction benchmarking and service optimization.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
21 transactions totaling $631 million
Supplies, Equipment & Services
30 transactions totaling $645 million
Healthcare IT & Managed Care
17 transactions totaling $45 million
Healthcare Facilities & Distributors
11 transactions totaling $132 million
Pharma & Biotech
38 transactions totaling $1,711 million
Supplies, Equipment & Services
25 transactions totaling $461 million
Healthcare IT & Managed Care
16 transactions totaling $332 million
Healthcare Facilities & Distributors
5 transactions totaling $158 million
Pharma & Biotech
20 transactions totaling $1,328 million
Supplies, Equipment & Services
8 transactions totaling $902 million
Healthcare IT & Managed Care
9 transactions totaling $7,318 million
Healthcare Facilities & Distributors
1 transaction totaling $1,400 million
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
May 21, 2021 - Contract Pharma
Premier Research is a provider of strategic and regulatory advisory services as well as clinical development services to the biotechnology, specialty pharma, and medical device industry. Camargo is a global strategy, regulatory, and commercial partner for emerging biopharma companies and has experience in complex development programs and accelerated approval pathways that leverages their expertise in areas such as oncology, pediatrics, rare disease, and 505(b)(2) product development.

May 20, 2021 - Contract Pharma
This new agreement is in addition to the 600 million doses already committed to the EU through 2021. The additional 900 million agreed doses are expected to be delivered on a monthly schedule beginning December 2021 and continuing into 2023. As part of the agreement, the EC also has an option to increase the number of doses delivered by up to an additional 900 million, bringing the total number of potential doses delivered to the EC, inclusive of all agreements, to up to 2.4 billion. All doses for the EC are planned to be manufactured in the EU.

May 20, 2021 - Fierce Pharma
As GSK forges ahead with its plan to split into two by next year, the pharma giant has unveiled plans to sell its entire stake in respiratory drug partner Innoviva for roughly $392 million.

May 19, 2021 - Fierce Biotech
Where there’s smoke there’s fire, and hot on the heels of closing more than a half-billion dollars in venture capital funding, Exscientia announced a drug discovery deal with Bristol Myers Squibb that could pay out up to $1.2 billion or more.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.